Relief Cardiovascular
Relief Cardiovascular, founded in 2022 and headquartered in Orange County, California, develops transcatheter implant systems to manage volume in heart failure. The company is developing a first-generation implantable system to modulate inferior vena cava flow with integrated hemodynamic monitoring; this system is planned to enter outside-the-US (OUS) clinical investigation in late 2025. The organization reports preclinical large-animal data supporting sustained control of venous pressures and implant safety and states experience in development, manufacture, and commercialization of catheter-based cardiovascular implants.
Industries
N/A
Nr. of Employees
small (1-50)
Relief Cardiovascular
3188 Airway Avenue, Suite K-1, Costa Mesa, CA 92626
Patents
Systems, devices, and methods for controllably and selectively occluding, restricting, and diverting flow within a patient's vasculature
US-12569251-B2
View DetailsSystems, devices, and methods for controllably and selectively occluding, restricting, and diverting flow within a patient's vasculature
US-11974751-B2
View DetailsSystems, devices, and methods for controllably and selectively occluding, restricting, and diverting flow within a patient's vasculature
US-11883030-B2
View Details
Systems, devices, and methods for controllably and selectively occluding, restricting, and diverting flow within a patient's vasculature
US-12569251-B2
View DetailsSystems, devices, and methods for controllably and selectively occluding, restricting, and diverting flow within a patient's vasculature
US-11974751-B2
View DetailsSystems, devices, and methods for controllably and selectively occluding, restricting, and diverting flow within a patient's vasculature
US-11883030-B2
View DetailsProducts
Transcatheter preload-modulating implant system (inferior vena cava flow modulation)
A first-generation transcatheter implantable system designed to modulate inferior vena cava flow to manage volume overload in heart failure, with integrated hemodynamic monitoring and the ability to adjust venous return for chronic use.
Transcatheter preload-modulating implant system (inferior vena cava flow modulation)
A first-generation transcatheter implantable system designed to modulate inferior vena cava flow to manage volume overload in heart failure, with integrated hemodynamic monitoring and the ability to adjust venous return for chronic use.
Expertise Areas
- Transcatheter cardiovascular implant development
- Heart failure therapeutics focused on preload modulation
- Implantable hemodynamic monitoring and control
- Preclinical large-animal testing
Key Technologies
- Transcatheter delivery systems
- Implantable hemodynamic sensors
- Closed-loop hemodynamic control systems
- Catheter-based inferior vena cava flow modulation
News & Updates
The first-generation implant system is stated to be entering outside-the-US (OUS) clinical investigation in late 2025.
Company established in 2022.
Reported preclinical chronic large-animal studies demonstrating sustained control of venous pressures, favorable histopathology, and long-term implant safety.
The first-generation implant system is stated to be entering outside-the-US (OUS) clinical investigation in late 2025.
Company established in 2022.
Reported preclinical chronic large-animal studies demonstrating sustained control of venous pressures, favorable histopathology, and long-term implant safety.